project id: TCGA-PRAD; case submitter id: TCGA-KC-A7F5; source center: 23; state: released; a260 a280 ratio: 1.91; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.52; rna integrity number: 8.5; age at index: 54; days to birth: -20015; ethnicity: not hispanic or latino; gender: male; race: white; vital status: Alive; year of birth: 1959; age at diagnosis: 20015; ajcc clinical m: M0; ajcc clinical t: T2c; ajcc pathologic n: N0; ajcc pathologic t: T2c; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 91.0; icd 10 code: C61; last known disease status: not reported; morphology: 8140/3; primary diagnosis: Adenocarcinoma, NOS; primary gleason grade: Pattern 4; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; secondary gleason grade: Pattern 3; site of resection or biopsy: Prostate gland; synchronous malignancy: No; tissue or organ of origin: Prostate gland; tumor grade: Not Reported; year of diagnosis: 2013; treatment or therapy: no; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 138; initial weight: 250.0; sample id: 12a21067-e911-4caf-ad87-9204360dc6c7; sample submitter id: TCGA-KC-A7F5-01A; portion id: dc30238a-50c7-4d04-8889-483fa8739e0c; portion submitter id: TCGA-KC-A7F5-01A-11; slide id: 20e9ad85-15a8-42a8-88dd-3834907d811b; slide submitter id: TCGA-KC-A7F5-01A-01-TSA; percent lymphocyte infiltration: 2.0; percent monocyte infiltration: 0.0; percent necrosis: 0.0; percent neutrophil infiltration: 0.0; percent normal cells: 0.0; percent stromal cells: 25.0; percent tumor cells: 75.0; percent tumor nuclei: 75.0; section location: TOP;